Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
Nichi-Iko Pharmaceutical on September 27 won Japan approval for a biosimilar version of Remicade (infliximab), which will be the first biosimilar for the company and the second follow-on for the big-seller anti-TNFα antibody. The generic major announced Zeria Pharmaceutical as…
To read the full story
Related Article
- Remicade Biosimilar Gets New Dosage Nod for Psoriasis, Crohn’s Disease: Nichi-Iko/Ayumi
June 21, 2018
- Nichi-Iko Rolls Out Remicade Biosimilar
November 29, 2017
- Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
September 19, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
BUSINESS
- Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
- Shionogi to Offload 2 China Generics Units in Pivot to Innovative Drugs
October 30, 2026
- Teijin Regenet Joins Global CGT CDMO Alliance as Founding Member
October 30, 2026
- FRONTEO, Maruho Expand AI Drug Discovery Partnership
October 30, 2026
- Tanabe Files Lymphoma ADC in Japan, Taps Nippon Shinyaku for Sales
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…